← Back to Patent Explorer
US5316765A Expired / Lapsed US ⏱️ 0.0 years remaining

Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies

Assignee: Folkers Karl Foundation for Biomedical and Clinical Research
•
Filing: 1991-09-19
•
Granted: 1994-05-31
•
Expires: 2011-09-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Disclosed are methods for inhibiting the side effects attendant treatment with HMG-CoA reductase inhibitors. Treatment of a patient with and HMG-CoA reductase inhibitor in combination with coenzyme Q 10 provides a reduction in patient cholesterol levels and guards against typical HMG-CoA reductase-inhibitor side effects, most notably liver dysfunction and cardiac dysfunction. The combination of lovastatin, an HMG-CoA reductase inhibitor, and coenzyme Q 10 in ratios of between 1:2 to 1:29 provide significant enhancement of a patient's caridac condition. By way of example, other HMG-CoA reductase inhibitors which may be included in the claimed combinations include pravastatin, compactin, fluvastatin, dalvastatin, simvastatin, BMY 22089, GR-95030, HR-780, CI-981, SQ 33,600, and BMY 22566 and XU-62-320.

Inventors

  • 👤 Karl A. Folkers
  • 👤 Per H. Langsjoen
  • 👤 Richard A. Willis

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 08:13
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/365

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 45 words
A method for ameliorating reductions of coenzyme Q 10 in cardiomyopathy patients receiving an HMG-CoA reductase inhibitor comprising administering concurrently with said HMG-CoA reductase inhibitor coenzyme Q 10 at a concentration sufficient to raise serum levels of coenzyme Q 10 to at least 2.0 μg/ml.
Claim 2
Independent Claim 45 words
A method for ameliorating reductions of coenzyme Q 10 in cardiomyopathy patients receiving an HMG-CoA reductase inhibitor comprising administering concurrently with said HMG-CoA reductase inhibitor coenzyme Q 10 at a concentration sufficient to raise serum levels of coenzyme Q 10 to at least 2.0 μg/ml.
Claim 3
Dependent Claim 37 words
The method of claim 1, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of: lovastatin; pravastatin; simvastatin; fluvastatin; dalvastatin; compactin; HR-780; B My 22,089; B My 22,566; SQ 33,600; GR 95,030; or CI 981.
Claim 4
Dependent Claim 12 words
The method of claim 1 wherein the HMG-CoA reductase inhibitor is pravastatin.
Claim 5
Dependent Claim 36 words
The method of claim 1 wherein the concentration of coenzyme Q 10 sufficient to raise serum levels of coenzyme Q 10 to at least 2.0 μg/ml is at least 200 mg/day for at least 30 days.

References Cited (Backward Citations)

US4231938A Cited
US4346227A Cited
US4444784A Cited
US4824669A Cited
US4885167A Cited
US4933165A Cited
US4929437A Cited
US5082650A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-05-30 1997-11-29 1998-05-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-05-30 2001-11-29 2002-05-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-05-30 2005-11-29 2006-05-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag